Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 ...

Compugen Ltd (CGEN) showcases promising clinical progress and a strong cash position, despite facing revenue and net loss hurdles in Q1 2026.

Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company ...

COM503 a potential first-in-class, high affinity anti- IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Compugen plans to file COM503 IND in 2024 "We are very excited to ...

HOLON, Israel, July 21, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered ...

HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first ...

Compugen (CGEN) is scheduled to announce Q1 earnings results on Monday, May 18th, after market close. The consensus EPS Estimate is -$0.08 (flat Y/Y) and the consensus Revenue Estimate is $1.26M (-45.

Compugen (CGEN) is maintained at a Buy rating, driven by advancing clinical programs and upcoming catalysts in oncology.

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will ...

The stock rose as high as 18.5% before falling a bit toward the close. Compugen may have benefitted from a turn toward growth stocks on Thursday in the markets. The company focuses on oncology ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...